Investigate the Effectiveness of Carbocisteine & Hypertonic Saline for Bronchiectasis Management
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on November 17th, 2025
|
Patients with bronchiectasis often experience excessive mucus production that interferes with normal respiratory function. Current clinical guidelines recommend the use of mucoactive medications and airway clearance agents to facilitate sputum expectoration, but these recommendations are largely based on low-quality evidence. To address this gap, the British government funded a study to evaluate the safety and efficacy of mucolytic therapy in bronchiectasis management.
The clinical study enrolled 288 participants diagnosed with bronchiectasis confirmed by computed tomography. All participants reported daily sputum production and had experienced at least two pulmonary exacerbations in the previous year. Among them, approximately half produced mucopurulent sputum, 30% had mucoid sputum, and the remainder had purulent sputum. Bacterial colonization was present in nearly 40% of patients, with over 10% colonized by *Pseudomonas* species.
Participants were randomly assigned to one of four groups: hypertonic saline alone, carbocisteine alone, a combination of both agents, or standard care. Carbocisteine was administered orally at 750 mg three times daily for eight weeks and then reduced to twice daily. Hypertonic saline (6%) was delivered via nebulization. Carbocisteine acts by disrupting disulfide bonds to reduce sputum viscosity, while hypertonic saline enhances mucus clearance by drawing water into the airway secretions.
After 52 weeks of treatment, the study found no significant reduction in pulmonary exacerbations in any of the intervention groups compared with standard care. Similarly, there was no meaningful improvement in patient-reported quality-of-life outcomes measured by the St. George’s Respiratory Questionnaire, the QoL-B scale, the EQ-5D-5L index, or the EQ-VAS score. The researchers concluded that while carbocisteine and hypertonic saline were safe, they did not confer measurable clinical benefits in this population, and future studies should explore alternative mucolytic agents such as N-acetylcysteine and guaifenesin at varying concentrations.
The clinical study enrolled 288 participants diagnosed with bronchiectasis confirmed by computed tomography. All participants reported daily sputum production and had experienced at least two pulmonary exacerbations in the previous year. Among them, approximately half produced mucopurulent sputum, 30% had mucoid sputum, and the remainder had purulent sputum. Bacterial colonization was present in nearly 40% of patients, with over 10% colonized by *Pseudomonas* species.
Participants were randomly assigned to one of four groups: hypertonic saline alone, carbocisteine alone, a combination of both agents, or standard care. Carbocisteine was administered orally at 750 mg three times daily for eight weeks and then reduced to twice daily. Hypertonic saline (6%) was delivered via nebulization. Carbocisteine acts by disrupting disulfide bonds to reduce sputum viscosity, while hypertonic saline enhances mucus clearance by drawing water into the airway secretions.
After 52 weeks of treatment, the study found no significant reduction in pulmonary exacerbations in any of the intervention groups compared with standard care. Similarly, there was no meaningful improvement in patient-reported quality-of-life outcomes measured by the St. George’s Respiratory Questionnaire, the QoL-B scale, the EQ-5D-5L index, or the EQ-VAS score. The researchers concluded that while carbocisteine and hypertonic saline were safe, they did not confer measurable clinical benefits in this population, and future studies should explore alternative mucolytic agents such as N-acetylcysteine and guaifenesin at varying concentrations.